The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Block BAFF induced mouse splenocyte survival. The expected ED50 for this effect is 2.0-4.0 µg/ml in the presence of 1.0 µg/ml of human soluble BAFF.
% SDS-PAGE. Purity: > 95% by SDS-PAGE and HPLC analyses. Endotoxin level < 0.1 ng per µg of BAFF-R
Concentration information loading...
Shipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid freeze / thaw cycles.
Endotoxin level: < 0.1 ng per µg of soluble BAFF.
This product is an active protein and may elicit a biological response in vivo, handle with caution.
Reconstitute in water to a concentration of 0.1-1.0 mg/ml.
This solution can be diluted into other aqueous buffers.
B cell activating factor receptor
B-cell-activating factor receptor
BLyS receptor 3
Tumor necrosis factor receptor subunit member 13C
Tumor necrosis factor receptor superfamily member 13C
B-cell receptor specific for TNFSF13B/TALL1/BAFF/BLyS. Promotes the survival of mature B-cells and the B-cell response.
Highly expressed in spleen and lymph node, and in resting B-cells. Detected at lower levels in activated B-cells, resting CD4+ T-cells, in thymus and peripheral blood leukocytes.
Defects in TNFRSF13C are the cause of immunodeficiency common variable type 4 (CVID4) [MIM:613494]; also called antibody deficiency due to BAFFR defect. CVID4 is a primary immunodeficiency characterized by antibody deficiency, hypogammaglobulinemia, recurrent bacterial infections and an inability to mount an antibody response to antigen. The defect results from a failure of B-cell differentiation and impaired secretion of immunoglobulins; the numbers of circulating B cells is usually in the normal range, but can be low.